Chronic stress is one of the major causes that lead to major depressive disorder (MDD), which is a prevalent mood disorder worldwide. Lots of MDD patients could not benefit from available medication due to the complex etiology of MDD. Recently, long non-coding RNAs (lncRNAs), molecular switches of downstream genes expression, have been reported to be involved in the pathogenesis of MDD. LncRNA TCONS_00019174 has been implicated in MDD risk and antidepressant effects, However, the effect of lncRNA TCONS_00019174 on antidepressant responses has not been investigated. This study is designed to determine whether altered expression of lncRNA TCONS_00019174 contributes to the depression-like behaviors associated with chronic stress. We found that mice exposed to chronic ultra-mild stress (CUMS) displayed apparent depression-like behaviors and decreased expression of lncRNA TCONS_00019174 in hippocampus. Both changed behaviors and lncRNA TCONS_00019174 expression level were rescued by chronic treatment of imipramine (IMI). Viral-mediated lncRNA TCONS_00019174 overexpression in hippocampal neurons improved behaviors of mice exposed to CUMS. Further, we found lncRNA TCONS_00019174 overexpression upregulated phosphorylated-GSK3β (p-GSK3β) protein and β-catenin in the hippocampus. These findings suggest that lncRNA TCONS_00019174 exerts antidepressant-like effect in mice by activating Wnt/β-catenin pathway, proposing that lncRNAs may serve as a potential therapeutic target for MDD in the clinical application.
ChattarjiS., TomarA., SuvrathanA., GhoshS. and RahmanM.M., Neighborhood matters: Divergent patterns of stress-induced plasticity across the brain, Nature neuroscience18 (2015), 1364–1375. doi:10.1038/nn.4115.
3.
CollingridgeG.L., PeineauS., HowlandJ.G. and WangY.T., Long-term depression in the CNS, Nature reviews Neuroscience11 (2010), 459–473. doi:10.1038/nrn2867.
4.
CuiX., SunX., NiuW., KongL., HeM., ZhongA., ChenS., JiangK., ZhangL. and ChengZ., Long non-coding RNA: Potential diagnostic and therapeutic biomarker for major depressive disorder, Medical science monitor: International medical journal of experimental and clinical research22 (2016), 5240–5248. doi:10.12659/MSM.899372.
5.
DavidD.J., SamuelsB.A., RainerQ., WangJ.W., MarstellerD., MendezI., DrewM., CraigD.A., GuiardB.P., GuillouxJ.P., ArtymyshynR.P., GardierA.M., GeraldC., AntonijevicI.A., LeonardoE.D. and HenR., Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression, Neuron62 (2009), 479–493. doi:10.1016/j.neuron.2009.04.017.
6.
DumanR.S. and AghajanianG.K., Synaptic dysfunction in depression: Potential therapeutic targets, Science338 (2012), 68–72. doi:10.1126/science.1222939.
7.
DwivediY., Emerging role of microRNAs in major depressive disorder: Diagnosis and therapeutic implications, Dialogues in clinical neuroscience16 (2014), 43–61.
8.
FanH.M., SunX.Y., GuoW., ZhongA.F., NiuW., ZhaoL., DaiY.H., GuoZ.M., ZhangL.Y. and LuJ., Differential expression of microRNA in peripheral blood mononuclear cells as specific biomarker for major depressive disorder patients, Journal of psychiatric research59 (2014), 45–52. doi:10.1016/j.jpsychires.2014.08.007.
9.
FranklinT.B., SaabB.J. and MansuyI.M., Neural mechanisms of stress resilience and vulnerability, Neuron75 (2012), 747–761. doi:10.1016/j.neuron.2012.08.016.
10.
GeJ.F., PengY.Y., QiC.C., ChenF.H. and ZhouJ.N., Depression-like behavior in subclinical hypothyroidism rat induced by hemi-thyroid electrocauterization, Endocrine45 (2014), 430–438. doi:10.1007/s12020-013-0001-4.
11.
GeaghanM. and CairnsM.J., MicroRNA and posttranscriptional dysregulation in psychiatry, Biological psychiatry78 (2015), 231–239. doi:10.1016/j.biopsych.2014.12.009.
12.
HendrickxH., McEwenB.S. and OuderaaF., Metabolism, mood and cognition in aging: The importance of lifestyle and dietary intervention, Neurobiology of aging26(Suppl 1) (2005), 1–5. doi:10.1016/j.neurobiolaging.2005.10.005.
13.
ImH.I. and KennyP.J., MicroRNAs in neuronal function and dysfunction, Trends in neurosciences35 (2012), 325–334. doi:10.1016/j.tins.2012.01.004.
14.
IsslerO. and ChenA., Determining the role of microRNAs in psychiatric disorders, Nature reviews Neuroscience16 (2015), 201–212. doi:10.1038/nrn3879.
15.
JopeR.S. and RohM.S., Glycogen synthase kinase-3 (GSK3) in psychiatric diseases and therapeutic interventions, Current drug targets7 (2006), 1421–1434. doi:10.2174/1389450110607011421.
16.
Kaidanovich-BeilinO., MilmanA., WeizmanA., PickC.G. and Eldar-FinkelmanH., Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus, Biological psychiatry55 (2004), 781–784. doi:10.1016/j.biopsych.2004.01.008.
17.
KaregeF., PerroudN., BurkhardtS., FernandezR., BallmannE., La HarpeR. and MalafosseA., Protein levels of beta-catenin and activation state of glycogen synthase kinase-3beta in major depression. a study with postmortem prefrontal cortex, Journal of affective disorders136 (2012), 185–188. doi:10.1016/j.jad.2011.09.024.
18.
KocerhaJ., DwivediY. and BrennandK.J., Noncoding RNAs and neurobehavioral mechanisms in psychiatric disease, Molecular psychiatry20 (2015), 677–684. doi:10.1038/mp.2015.30.
KrishnanV. and NestlerE.J., The molecular neurobiology of depression, Nature455 (2008), 894–902. doi:10.1038/nature07455.
21.
KussA.W. and ChenW., MicroRNAs in brain function and disease, Current neurology and neuroscience reports8 (2008), 190–197. doi:10.1007/s11910-008-0031-0.
22.
LiX. and JopeR.S., Is glycogen synthase kinase-3 a central modulator in mood regulation?Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology35 (2010), 2143–2154. doi:10.1038/npp.2010.105.
23.
McEwenB.S., BowlesN.P., GrayJ.D., HillM.N., HunterR.G., KaratsoreosI.N. and NascaC., Mechanisms of stress in the brain, Nature neuroscience18 (2015), 1353–1363. doi:10.1038/nn.4086.
24.
NumataS., IshiiK., TajimaA., IgaJ., KinoshitaM., WatanabeS., UmeharaH., FuchikamiM., OkadaS., BokuS., HishimotoA., ShimoderaS., ImotoI., MorinobuS. and OhmoriT., Blood diagnostic biomarkers for major depressive disorder using multiplex DNA methylation profiles: Discovery and validation, Epigenetics10 (2015), 135–141. doi:10.1080/15592294.2014.1003743.
25.
O'ConnorR.M., DinanT.G. and CryanJ.F., Little things on which happiness depends: MicroRNAs as novel therapeutic targets for the treatment of anxiety and depression, Molecular psychiatry17 (2012), 359–376. doi:10.1038/mp.2011.162.
26.
OquendoM.A., McGrathP. and WeissmanM.M., Biomarker studies and the future of personalized treatment for depression, Depression and anxiety31 (2014), 902–905. doi:10.1002/da.22300.
27.
PeiferM. and PolakisP., Wnt signaling in oncogenesis and embryogenesis – A look outside the nucleus, Science287 (2000), 1606–1609. doi:10.1126/science.287.5458.1606.
28.
Pilar-CuellarF., VidalR. and PazosA., Subchronic treatment with fluoxetine and ketanserin increases hippocampal brain-derived neurotrophic factor, beta-catenin and antidepressant-like effects, British journal of pharmacology165 (2012), 1046–1057. doi:10.1111/j.1476-5381.2011.01516.x.
29.
PonjavicJ., OliverP.L., LunterG. and PontingC.P., Genomic and transcriptional co-localization of protein-coding and long non-coding RNA pairs in the developing brain, PLoS genetics5 (2009), Article ID e1000617. doi:10.1371/journal.pgen.1000617.
30.
PorsoltR.D., BertinA. and JalfreM., Behavioral despair in mice: A primary screening test for antidepressants, Archives internationales de pharmacodynamie et de therapie229 (1977), 327–336.
31.
SantarelliL., SaxeM., GrossC., SurgetA., BattagliaF., DulawaS., WeisstaubN., LeeJ., DumanR., ArancioO., BelzungC. and HenR., Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants, Science301 (2003), 805–809. doi:10.1126/science.1083328.
32.
SchmidtH.D., SheltonR.C. and DumanR.S., Functional biomarkers of depression: Diagnosis, treatment, and pathophysiology, Neuropsychopharmacology: Official publication of the American College of Neuropsychopharmacology36 (2011), 2375–2394. doi:10.1038/npp.2011.151.
33.
SeibenhenerM.L. and WootenM.W., Isolation and culture of hippocampal neurons from prenatal mice, J. Vis. Exp.65 (2012), Article ID e3634. doi:10.3791/3634.
34.
SongH.T., SunX.Y., ZhangL., ZhaoL., GuoZ.M., FanH.M., ZhongA.F., NiuW., DaiY.H., ZhangL.Y., ShiZ., LiuX.P. and LuJ., A preliminary analysis of association between the down-regulation of microRNA-181b expression and symptomatology improvement in schizophrenia patients before and after antipsychotic treatment, Journal of psychiatric research54 (2014), 134–140. doi:10.1016/j.jpsychires.2014.03.008.
35.
SongM.F., DongJ.Z., WangY.W., HeJ., JuX., ZhangL., ZhangY.H., ShiJ.F. and LvY.Y., CSF miR-16 is decreased in major depression patients and its neutralization in rats induces depression-like behaviors via a serotonin transmitter system, Journal of affective disorders178 (2015), 25–31. doi:10.1016/j.jad.2015.02.022.
36.
SunX.Y., LuJ., ZhangL., SongH.T., ZhaoL., FanH.M., ZhongA.F., NiuW., GuoZ.M., DaiY.H., ChenC., DingY.F. and ZhangL.Y., Aberrant microRNA expression in peripheral plasma and mononuclear cells as specific blood-based biomarkers in schizophrenia patients, Journal of clinical neuroscience: official journal of the Neurosurgical Society of Australasia22 (2015), 570–574. doi:10.1016/j.jocn.2014.08.018.
37.
UchidaS., HaraK., KobayashiA., FujimotoM., OtsukiK., YamagataH., HobaraT., AbeN., HiguchiF., ShibataT., HasegawaS., KidaS., NakaiA. and WatanabeY., Impaired hippocampal spinogenesis and neurogenesis and altered affective behavior in mice lacking heat shock factor 1, Proceedings of the National Academy of Sciences of the United States of America108 (2011), 1681–1686. doi:10.1073/pnas.1016424108.
38.
UchidaS., HaraK., KobayashiA., OtsukiK., YamagataH., HobaraT., SuzukiT., MiyataN. and WatanabeY., Epigenetic status of Gdnf in the ventral striatum determines susceptibility and adaptation to daily stressful events, Neuron69 (2011), 359–372. doi:10.1016/j.neuron.2010.12.023.
39.
VialouV., FengJ., RobisonA.J. and NestlerE.J., Epigenetic mechanisms of depression and antidepressant action, Annual review of pharmacology and toxicology53 (2013), 59–87. doi:10.1146/annurev-pharmtox-010611-134540.
40.
VoletiB. and DumanR.S., The roles of neurotrophic factor and Wnt signaling in depression, Clinical pharmacology and therapeutics91 (2012), 333–338. doi:10.1038/clpt.2011.296.
41.
WanY., LiuY., WangX., WuJ., LiuK., ZhouJ., LiuL. and ZhangC., Identification of differential microRNAs in cerebrospinal fluid and serum of patients with major depressive disorder, PloS one10 (2015), Article ID e0121975. doi:10.1371/journal.pone.0121975.
42.
YangF., ZhangL., HuoX.S., YuanJ.H., XuD., YuanS.X., ZhuN., ZhouW.P., YangG.S., WangY.Z., ShangJ.L., GaoC.F., ZhangF.R., WangF. and SunS.H., Long noncoding RNA high expression in hepatocellular carcinoma facilitates tumor growth through enhancer of zeste homolog 2 in humans, Hepatology54 (2011), 1679–1689. doi:10.1002/hep.24563.
43.
YuX. and MalenkaR.C., Beta-catenin is critical for dendritic morphogenesis, Nature neuroscience6 (2003), 1169–1177. doi:10.1038/nn1132.
